Sprowl Jason A, Lancaster Cynthia S, Pabla Navjotsingh, Hermann Edwin, Kosloske Ashley M, Gibson Alice A, Li Lie, Zeeh Dorothea, Schlatter Eberhard, Janke Laura J, Ciarimboli Giuliano, Sparreboom Alex
Departments of Pharmaceutical Sciences and.
Klinik für Urologie and.
Clin Cancer Res. 2014 Aug 1;20(15):4026-35. doi: 10.1158/1078-0432.CCR-14-0319. Epub 2014 Jun 10.
Tubular secretion of cisplatin is abolished in mice deficient for the organic cation transporters Oct1 and Oct2 (Oct1/2(-/-)mice), and these animals are protected from severe cisplatin-induced kidney damage. Since tubular necrosis is not completely absent in Oct1/2(-/-)mice, we hypothesized that alternate pathways are involved in the observed injury.
Studies were done in wild-type, Oct1/2(-/-), or p53-deficient animals, all on an FVB background, receiving cisplatin intraperitoneally at 15 mg/kg. Cisplatin metabolites were analyzed using mass spectrometry, and gene expression was assessed using Affymetrix microarrays and RT-PCR arrays.
KEGG pathway analyses on kidneys from mice exposed to cisplatin revealed that the most significantly altered genes were associated with the p53 signaling network, including Cdnk1a and Mdm2, in both wild-type (P = 2.40 × 10(-11)) and Oct1/2(-/-)mice (P = 1.92 × 10(-8)). This was confirmed by demonstrating that homozygosity for a p53-null allele partially reduced renal tubular damage, whereas loss of p53 in Oct1/2(-/-)mice (p53(-/-)/Oct1/2(-/-)) completely abolished nephrotoxicity. We found that pifithrin-α, an inhibitor of p53-dependent transcriptional activation, inhibits Oct2 and can mimic the lack of nephrotoxicity observed in p53(-/-)/Oct1/2(-/-)mice.
These findings indicate that (i) the p53 pathway plays a crucial role in the kidney in response to cisplatin treatment and (ii) clinical exploration of OCT2 inhibitors may not lead to complete nephroprotection unless the p53 pathway is simultaneously antagonized.
在缺乏有机阳离子转运体Oct1和Oct2的小鼠(Oct1/2(-/-)小鼠)中,顺铂的肾小管分泌被消除,并且这些动物免受严重的顺铂诱导的肾损伤。由于Oct1/2(-/-)小鼠中并非完全不存在肾小管坏死,我们推测其他途径参与了所观察到的损伤。
在野生型、Oct1/2(-/-)或p53缺陷型动物(均为FVB背景)中进行研究,这些动物腹腔注射15 mg/kg顺铂。使用质谱分析顺铂代谢产物,并使用Affymetrix微阵列和RT-PCR阵列评估基因表达。
对接受顺铂处理的小鼠肾脏进行的KEGG通路分析显示,在野生型(P = 2.40×10(-11))和Oct1/2(-/-)小鼠(P = 1.92×10(-8))中,最显著改变的基因与p53信号网络相关,包括Cdnk1a和Mdm2。通过证明p53无效等位基因的纯合性部分减轻肾小管损伤,而Oct1/2(-/-)小鼠(p53(-/-)/Oct1/2(-/-))中p53的缺失完全消除肾毒性,这一点得到了证实。我们发现pifithrin-α,一种p53依赖性转录激活的抑制剂,抑制Oct2,并可模拟在p53(-/-)/Oct1/2(-/-)小鼠中观察到的肾毒性缺乏。
这些发现表明,(i)p53通路在肾脏对顺铂治疗的反应中起关键作用,并且(ii)除非同时拮抗p53通路,否则OCT2抑制剂的临床探索可能不会导致完全的肾保护。